Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units The company expects to decide the best path by year-end 2026. "MRD Clinical Portfolio - Pipeline." Credit: Adaptive Biotechnologies Subscribe now Already have an account? Sign in.
